Table 1 Patient characteristics and clinical and molecular findings
Patient # | Pathology | Primary site/Recurrence | DFI from surgery to relapse (mos) | Number of lines before P | Duration of P treatment (mos) | Duration of P + S treatment (mos) | Best RECIST response | Best Choi response | P dose (mg) | S dose (mg) | Procedures while on P + S | Toxicity | Status | Genomic profile by FoundationOne |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | SFT | Lung/Lung + heart | 10 | 0 | 4 | 2 | PD | PD | 400 | 4 | AWD | |||
2 | SFT | Pleura/Duadenum + Spleen + liver | 13 | 0 | 8 | 2 | PD | PD | 600 | 4 | Lethargy | Dead | NAB2-STAT6 fusion | |
TP53 P278S | ||||||||||||||
AXIN1 A740T | ||||||||||||||
BRD4 truncation exon 8 | ||||||||||||||
3 | UPS | Limb/Lung | 24 | 3 | 22 | 2 | PD | PD | 800 | 3 | Dead | |||
4 | UPS | Gluteus/Lung + pleura | 41 | 3 | 6 | 5 | PR | PR | 200 | 4 | Glucose intolerance-metformin | Dead | ||
5 | ULMS | Uterus/Lung | 13 | 2 | 8 | 16 on going | SD | PR | 400 | 3 | Metastasectomy and SBRT | Sub-febrile fever, glu intolerance-metformin | AWD | ALK IGFGP5-ALK fusion |
TSC2 splice site* | ||||||||||||||
CDKN2A loss | ||||||||||||||
TP53 L330P | ||||||||||||||
6 | LMS | Limb/Lung | 14 | 1 | 28 | 5 | SD | PR | 400 | 3 | Bowel perforation | AWD | ||
7 | DSRCT | Retroperitoneum | 0 | 3 | 12 | 11 | SD | PR | 200 | 3 | Proteinuria | Dead | ||
8 | UUS | Uterus/Lung + retroperitoneum | 3 | 1 | 4 | 1 | PD | PD | 400 | 4 | Dead | |||
9 | Chondrosarcoma grade II | Limb/Lung | 47 | 1 | 0 | 3 on going | SD | PR | 400 | 4 | AWD | CKS1B amplification | ||
MEF2C amplification |